Pharmaceutical Business Review
On a non-GAAP basis, net income rose 12% to $1.04bn from $928m.
Pharmaceutical Business Review
On a non-GAAP basis, net income rose 12% to $1.04bn from $928m.
Pharmaceutical Business Review
On a non-GAAP basis, net income rose 12% to $1.04bn from $928m.